This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR)	<p>Mouse studies suggest anti-uPAR antibodies could help treat aggressive breast cancer. In a mouse xenograft model for triple-negative breast cancer, two different anti-uPAR human antibodies inhibited tumor growth. In the same mouse model, a radiotherapeutic-conjugated variant of one of the antibodies caused tumor regression. Next steps include generating sufficient quantities of GMP material for a clinical trial.</p> <p>SciBX 6(9); doi:10.1038/scibx.2013.211 Published online March 7, 2013</p>	<p>Patent applications filed covering uPAR-binding agents and their methods of use; available for licensing from the University of California, San Francisco Office of Technology Management</p>	<p>LeBeau, A.M. <i>et al. Cancer Res.</i>; published online Feb. 11, 2013; doi:10.1158/0008-5472.CAN-12-3526 Contact: Charles S. Craik, University of California, San Francisco, Calif. e-mail: charles.craik@ucsf.edu</p>